Volume 2, Issue 3 (2023)                   GMJM 2023, 2(3): 1001-1004 | Back to browse issues page



How to cite this article
Günther J., Schneider I., Krämer A.. Carvone Prevents and Alleviates Hepatic Steatosis in Rat Model with Nonalcoholic Fatty Liver Disease. GMJM 2023; 2 (3) :1001-1004
URL: http://gmedicine.de/article-2-228-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rights and permissions
1- Department of Phytochemistry, Institute for Phytochemical Research (IPR), Berlin, Germany
Abstract   (222 Views)
Aims: Nonalcoholic fatty liver disease (NAFLD) is known as condition in which fat significantly aggregates in the liver and the use of antioxidants can alleviate its adverse effects. This study was aims to evaluate the effects of carvone on hepatic steatosis and NAFLD by investigation of the lipids in serum and liver.
Materials & Methods: Animals were grouped into four groups and studied for 42 days, including rats fed with 1) control diet (Control), 2) high fat diet (HF), 3) HF+50 mg/kg body weight of carvone (50 Carv) and HF+100 mg/kg body weight of carvone (100 Carv). Animals were killed, and blood and liver samples were obtained to evaluate the biochemical analyses including triglyceride, cholesterol, nonesterified fatty acids and thiobarbituric acid-reactive substances (TBARS).
Findings: Rats fed with HF diet showed higher levels for TBARS, triglycerides and cholesterol in comparison to control group (p<0.05). Dietary inclusion of carvone, especially in the higher levels, could reverse effects of HF on TBARS, cholesterol and triglycerides (p<0.05).
Conclusion: Carvone can alleviate hepatic steatosis in animals with NAFLD. It can be suggested to use of the carvone for patients with NAFLD.